A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements, the Food and Drug Administration announced today. The government alleges that Guardian Pharmacy Services distributed purportedly sterile drug products made under unsanitary conditions and in violation of current good manufacturing practice requirements. According to the complaint, the company also made and distributed misbranded drugs because their labels did not include adequate directions for patient use, were false or misleading. In 2017, the FDA received adverse event reports concerning at least 43 patients who received eye injections during cataract surgery of a drug compounded by Guardian.

Related News Articles

Headline
The U.S. Food and Drug Administration May 23 authorized marketing of a diagnostic test for detecting Zika virus antibodies in human blood.
Headline
The Joint Commission yesterday recommended that health care organizations review cleaning and disinfection instructions for tonometers and other ophthalmology…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Blog
America’s hospitals and health systems are dedicated to doing everything possible for patients, particularly when they need emergency care and as a place for…
Headline
Hospitals, health systems and other health care organizations can sign up this week to host an intern for this year's Institute for Diversity and Health Equity…
Headline
The Centers for Disease Control and the National Tuberculosis Controllers Association this week released updated recommendations for TB screening and testing…